The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

Crescent Biopharma shares rose in premarket trading Thursday after announcing a Kelun‑Biotech partnership and new pipeline developments, which include three programs slated for 2026 trials. Shares ...

Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

New Jersey-based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...